(Health-NewsWire.Net, January 31, 2018 ) Rising prevalence of chronic diseases associated with thrombotic disease require long-term administration of antithrombotic drugs, which is the key factor enhancing the demand for antithrombotic drugs market. Furthermore, growing geriatric population, increasing hereditary diseases, lack of physical activity, increasing awareness among patients about life-threatening diseases, changing lifestyles and increasing hypertension are the factors favouring market growth. However, off- patented drugs, postoperative bleeding and availability of generic antithrombotic drugs would restrict the antithrombotic drugs market growth. Furthermore, new product launches by key vendors, up-gradation in the antithrombotic drugs and recent R&D programs by major players to develop new drugs are the key opportunities for the market.
For more information about this report: http://www.reportsweb.com/antithrombotic-drugs-global-market-outlook-2016-2022 Asia Pacific is expected to grasp major revenue and volume share in antithrombotic drugs market and is expected to grow with a high CAGR during the forecast period. This growth is attributed to increasing patient population in China and India. North America and Europe regions have significant penetration of antithrombotic drugs due to continual R&D activities for new drug development and high prevalence rate of cardiac and cancer diseases.
Some of the key global players in antithrombotic drugs market are Bayer AG, Johnson & Johnson Services Inc., Sanofi, Boehringer Ingelheim GmbH, Pfizer Inc., Abbott laboratories, Dr. Reddy's Laboratories, Pharmacia Inc., Eli Lilly and Company, The Medicines Company, Genentech Inc., Bristol-Myers Squibb., Watson laboratories inc, Zydus pharmaceuticals Inc. and Otsuka.
Drug Types Covered: -Anticoagulant -Thrombolytic drugs -Antiplatelet
Drug Classes Covered: -Edoxaban -Fondaparinux -Heparin -Apixaban -Debigatran -Rivaroxaban
Indications Covered: -Myocardial infarction (MI) -Venous thromboembolism (VTE) -Stroke -Acute coronary syndrome (ACS) -Peripheral arterial occlusion (PAO) -Other Indications
Route of Administration Covered: -Oral route -Parenteral route
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001716552/sample
Applications Covered: -Blood clot prevention -Hyperlipidemia treatment -Prophylactic treatment -Thromboembolic disease treatment -Other Applications
Distribution Channels Covered: -Hospital Pharmacies -Online Retailers -General Pharmacies -Drug Stores
Regions Covered: -North America -US -Canada -Mexico -Europe -Germany -France -Italy -UK -Spain -Rest of Europe -Asia Pacific -Japan -China -India -Australia -New Zealand -Rest of Asia Pacific - Rest of the World -Middle East -Brazil -Argentina -South Africa -Egypt
Company Profiling 13.1 Bayer AG 13.2 Johnson & Johnson Services Inc. 13.3 Sanofi 13.4 Boehringer Ingelheim GmbH 13.5 Pfizer Inc. 13.6 Abbott laboratories 13.7 Dr. Reddy's Laboratories 13.8 Pharmacia Inc. 13.9 Eli Lilly and Company 13.10 The Medicines Company 13.11 Genentech Inc. 13.12 Bristol-Myers Squibb. 13.13 Watson laboratories inc 13.14 Zydus pharmaceuticals Inc. 13.15 Otsuka
Inquire before Buying at http://www.reportsweb.com/inquiry&RW0001716552/buying
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
|